Discussions marquées : IVAC

IVAC VIMS Report on Global Vaccine Introduction - January 2015 (Now with IPV)

Thuy-Linh Nguyen Publié dans :
The January 2015 edition of the IVAC VIMS Report on Global Vaccine Introduction is now available at http://www.jhsph.edu/research/centers-and-institutes/ivac/vims/IVAC-VIMS-Report-2015-Jan.pdf

New in the January edition is the addition of an inactivated polio vaccine (IPV) section in the report.

IVAC VIMS Report on Global Vaccine Introduction - September 2014

Thuy-Linh Nguyen Publié dans :
The IVAC VIMS Report on Global Vaccine Introduction - September 2014 is out!

Recent updates (since March 2014) include:

-South Sudan's introduction of Haemophilus influenzae type b (Hib) vaccine in July 2014 marks a significant milestone in global health, as Hib-containing pentavalent vaccine is now available in all 73 Gavi countries. To read IVAC's reflections on this historic moment, click here.
-Pneumococcal conjugate vaccine (PCV) has been introduced in Niger, Republic of Korea, Swaziland, and Togo.
-Rotavirus vaccine has been introduced in Angola, Cameroon, Congo, Djibouti, Eritrea, Estonia, Kenya, Madagascar, New Zealand, Niger, Sierra Leone, Togo, Uzbekistan, and Zimbabwe.



The VIMS report displays data and figures on the introduction status of Hib, pneumococcal, and rotavirus vaccines both globally and in the 73 Gavi-eligible countries. The images and text in the report describe:

-How many countries have introduced each vaccine or plan to in the future
-National levels of vaccine coverage and access, globally and in Gavi countries
-Vaccine introduction trends over time
-Vaccine introduction status of each of the 194 countries, listed individually


This report is produced on a quarterly basis. Current and past reports can be accessed at http://www.jhsph.edu/research/centers-and-institutes/ivac/vims/

Vacancy: Advocacy & communications officer, International Vaccine Access Center (IVAC)

Thuy-Linh Nguyen Publié dans :
About IVAC
The mission of the International Vaccine Access Center (IVAC) at Johns Hopkins Bloomberg School of Public Health is to accelerate global access to life-saving vaccines through the development and implementation of evidence-based policies. IVAC contributes across the vaccine value chain, focusing on the generation and interpretation of evidence and translation into policies, vaccine introduction, implementation, and optimization. Our value lies in the combination of content knowledge and domain expertise. We work collaboratively across the fields of vaccine economics, epidemiology, clinical trials, modeling, advocacy, and policy, and across viral, bacterial, and parasitic pathogens and disease syndromes.

IVAC is seeking an Advocacy & Communications Officer for its Policy, Advocacy & Communications (PA&C) team. The PA&C team conducts a variety of strategic communications, policy, and advocacy activities aimed at increasing vaccine access in low- and middle-income countries. This A&C officer would primarily support our India advocacy project focused on accelerating introduction and uptake of rotavirus, pneumococcal, and Hib vaccines in India as part of a comprehensive approach to diarrhea and pneumonia control. The A&C officer will be responsible for developing a portfolio of materials that translate the evidence base for vaccines into messages and materials tailored for a variety of audiences, particularly developing country decision makers. In addition, the A&C officer would support other communications efforts and assist across the PA&C team as needed.

Responsibilities

Develop a portfolio of evidence-based materials including fact sheets, slides, brochures, talking points, messaging documents, etc. that translate technical concepts and published literature into messages for diverse audiences ranging from policy makers to the general public
Facilitate review of advocacy and media materials by technical experts to ensure messages are scientifically accurate but easy to understand
Review and summarize the latest vaccine research, news, and events that support IVAC’s efforts
Research, write and edit content for blogs, newsletters, websites and external media pieces
Identify and monitor scheduled project deliverables, milestones, and required tasks
Provide additional support to the PA&C team as needed

Qualifications
[list]
Masters degree in public health and 1-3 years of experience (or bachelor’s degree and 5 years of experience)
Knowledge of vaccines, pneumonia, diarrhea and other major global infectious diseases as well as understanding of basic epidemiologic and statistical concepts
Strong verbal and written communication skills as well as excellent interpersonal skills; demonstrated ability to write in a clear and organized fashion and translate technical concepts for lay audiences
Knowledge and experience of global health policy preferred
Communications, advocacy or journalism experience preferred
Highly organized and detail-oriented
Self-motivated and able to work well independently
Demonstrated problem solving and analytic skills
Ability to manage multiple projects successfully, and perhaps under tight deadlines
Available for overseas travel up to 15%

Interested applicants should apply here: https://hrnt.jhu.edu/jhujobs/job_view.cfm?view_req_id=62890&view=sch

IVAC VIMS Report on Global Vaccine Introduction - December 2013

Thuy-Linh Nguyen Publié dans :
IVAC-VIMS-Dec-2013-Report.pdf

This report provides data and figures on the introduction status of Haemophilus influenzae type b (Hib), pneumococcal, and rotavirus vaccines both globally and in 73 GAVI-eligible countries using information stored in the Vaccine Information Management System (VIMS) online database, managed by the International Vaccine Access Center (IVAC) at the Johns Hopkins Bloomberg School of Public Health. The images and text describe how many countries have introduced each vaccine or plan to in the future, global and GAVI rates of coverage and access, historical trends of the rate of introduction globally, and the vaccine introduction status of every country individually.

This report is produced on a quarterly basis. Current and past reports can be accessed at www.jhsph.edu/research/centers-and-institutes/ivac/vims/

For any questions regarding VIMS or the VIMS reports, please contact [email=vims@jhsph.edu]vims@jhsph.edu[/email].

International Vaccine Access Center (IVAC) Meeting 2012

Moderator Publié dans :
IVAC held a 2-day roundtable meeting with about 40 experts and observers in Washington, DC on May 9th and 10th to review the available evidence and develop a framework for improving decision-making related to vaccine vial size, and understand the economics of vaccine choice.

Here is a list of presentation summaries and documents:

Primary Container Considerations for Prequalification
Andrew Meek, World Health Organization [ View PDF ]
Outlines mandatory, critical, and preferred vaccine characteristics concerning programmatic suitability for WHO prequalification. Addresses removal of preservative thiomersal, including lack of alternatives and consequences of removal on immunization programs. Also describes prequalification and future challenges for Synflorix 2-dose presentation.

Considerations for Primary Vaccine Containers. IFPMA Perspectives: What are the Issues?
Jules Millogo, International Federation of Pharmaceutical Manufacturers and Associations [ View PDF ]
Introduces IFPMA, a non-profit representing the research-based pharmaceutical industry worldwide. Discusses details of manufacturing, technical, financial, patient and practitioner considerations, and secondary packaging considerations. Concludes stating that parameters for primary container selection are complex and multiple, and patient and provider considerations drive decision-making.

Primary Vaccine Container Selection in Developing Countries Safety
Neal Halsey, Johns Hopkins Bloomberg School of Public Health [ View PDF]
Addresses surveillance systems for adverse events following immunization, vaccine presentations, preservatives, and contamination and needlesticks. Errors in vaccine administration occur everywhere, although no true rate data exist. Surveillance systems and staff training and supervision are also inadequate. Simpler vaccine administration methods reduce errors. Pre-filled single-use syringes are easiest and safest, but also expensive and bulky, and may not be practical. Contamination of multi-dose vials has resulted in outbreaks and deaths globally. Preservatives are effective but have several manufacturing and delivery vulnerabilities.

Primary Vaccine Container Selection Bangladesh Perspectives
Tajul Islam Abdul Bari, Ministry of Health Bangladesh [ View PDF ]
Covers Bangladesh’s vaccine schedule, delivery system, cold chain, multi-dose vial policy, vaccine wastage, and plans for new vaccine introduction. Bangladesh has no major administration safety problems, although cost, cold chain management, vaccine supply, and vaccine wastage are all important issues for the country.

Primary Vaccine Container Roundtable: Modeling
Bruce Y. Lee, University of Pittsburg [ View PDF ]
Presents the Vaccine Modeling Initiative’s HERMES, a computational tool to design, plan, and manage vaccine supply chains. Discusses impact of rotavirus and pneumococcal vaccine introduction in Niger and Thailand. Other important vaccine supply factors considered are cost, vial size, capacity utilization, and vaccine availability.

Cold Chain, Disposal Volumes, Current Status and Future Trends
S. Kone, WHO/IVB [ View PDF ] [ View PDF - Vaccine Presentations ]
This presentation provides an overview of major elements in immunization systems, along with information about the operations impact of vaccine characteristics such as price, presentation, and formulation. Data from the Democratic Republic of Congo and Chad demonstrate the challenges of vaccine volume changes and increased workload.

Considerations for Primary Container Decisions: DCVMN Perspective
Suresh S. Jadhav, Serum Institute of India / DCVMN [ View PDF ]
Introduces the DCVMN, an alliance of vaccine manufacturers from developing countries that aims to ensure a consistent supply of quality vaccines for developing countries. Presents manufacturers perspectives on cost, vial size, and preservatives. Discusses implications for transition from multi-dose vials to single-dose presentations.

Immunization Session Attendance, Vaccine Wastage and Coverage
Philippe Jaillard, Agence de Médecine Préventive [ View PDF ]
Presents a study conducted by AMP to measure session attendance and calculate wastage in urban and rural areas of Burkina Faso (2009). Main conclusions were: session organization differed by setting, successful strategies exist to limit wastage without reducing coverage, and vial size may be impact quality. Lists areas for further research.


For further questions on the roundtable or framework, please contact [email=lprivord@jhsph.edu]Lois Privor-DummLois Privor-Dumm[/email], Director of Alliances and Information at IVAC.
  • Page :
  • 1